Skip to main content

Published locations for Tafasitamab+lenalidomide provides survival benefit over pola-BR and R2 in relapsed or refractory DLBCL

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Tafasitamab+lenalidomide provides survival benefit over pola-BR and R2 in relapsed or refractory DLBCL

User login

  • Reset your password
  • /content/tafasitamablenalidomide-provides-survival-benefit-over-pola-br-and-r2-relapsed-or-refractory
  • /b-cell-lymphoma-icymi/article/263732/b-cell-lymphoma/tafasitamablenalidomide-provides-survival